CNTX - Context Therapeutics Inc.

QQQ $ 612.14 $ 1.56 (0.26 %)

DIA $ 470.45 $ 1.64 (0.35 %)

SPY $ 672.31 $ 2.95 (0.44 %)

TLT $ 89.45 $ -0.19 (-0.21 %)

GLD $ 367.77 $ 0.35 (0.1 %)

Previous Close

$ 1.12

Open

$ 1.07

Bid

$ 1.04 x 1,000

Ask

$ 1.25 x 105

Day's Range

$ 1.04 - $ 1.13

52 Week Range

$ 0.49 - $ 2.10

Volume

198,861

Average Volume

Market Cap

102.9M

Beta (5Y Monthly)

$ 1.45

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	11-05-2025	09-30-2025	10-Q
2	08-06-2025	06-30-2025	10-Q
3	05-07-2025	03-31-2025	10-Q
4	03-20-2025	12-31-2024	10-K
5	11-06-2024	09-30-2024	10-Q
6	08-07-2024	06-30-2024	10-Q
7	05-08-2024	03-31-2024	10-Q
8	03-21-2024	12-31-2023	10-K
9	11-09-2023	09-30-2023	10-Q
10	08-09-2023	06-30-2023	10-Q
11	05-10-2023	03-31-2023	10-Q
12	03-22-2023	12-31-2022	10-K
13	11-09-2022	09-30-2022	10-Q
14	08-11-2022	06-30-2022	10-Q
15	05-11-2022	03-31-2022	10-Q
16	03-23-2022	12-31-2021	10-K
17	12-02-2021	09-30-2021	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Context Therapeutics Showcases CT-95 And C...
11/07/2025 12:42:49

D. Boral Capital Maintains Buy on Context ...
11/06/2025 13:22:07

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

HC Wainwright & Co. Maintains Buy on Conte...
11/06/2025 11:52:23

HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and raises the price ta...

Context Therapeutics Q3 EPS $(0.10) Misses...
11/05/2025 22:02:49

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.10) per share which missed the analyst consensus estimate o...

Context Therapeutics Amends Sales Agreemen...
10/24/2025 20:11:09

-SEC Filing

D. Boral Capital Maintains Buy on Context ...
10/16/2025 12:40:50

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

Context Therapeutics To Present Cancer Imm...
10/06/2025 11:38:40

Context Therapeutics Inc. ("Context" or the "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical compan...

this-synopsys-analyst-begins-coverage-on-a-bearish-note-here-are-top-5-initiations-for-thursday

This Synopsys Analyst Begins Coverage On A...
10/02/2025 18:26:09

Cantor Fitzgerald Initiates Coverage On Co...
10/02/2025 12:40:08

Cantor Fitzgerald analyst Li Watsek initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Overweight rating.

Guggenheim Initiates Coverage On Context T...
09/18/2025 13:02:36

Guggenheim analyst Paul Jeng initiates coverage on Context Therapeutics (NASDAQ:CNTX) with a Buy rating and announces Price ...

D. Boral Capital Maintains Buy on Context ...
08/07/2025 11:39:00

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

HC Wainwright & Co. Maintains Buy on Conte...
08/07/2025 10:57:38

HC Wainwright & Co. analyst Emily Bodnar maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and lowers the price ta...

Context Therapeutics Q2 EPS $(0.09) Misses...
08/06/2025 20:59:24

Piper Sandler Reiterates Overweight on Con...
06/26/2025 16:40:34

Piper Sandler analyst Biren Amin reiterates Context Therapeutics (NASDAQ:CNTX) with a Overweight and lowers the price target...

12-health-care-stocks-moving-in-thursdays-pre-market-session

12 Health Care Stocks Moving In Thursday's...
06/05/2025 12:08:31

Context Therapeutics Is Presenting A Trial...
06/02/2025 11:33:53

D. Boral Capital Maintains Buy on Context ...
05/08/2025 11:30:13

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.

Context Therapeutics Q1 EPS $(0.05) Beats ...
05/07/2025 21:27:07

Context Therapeutics (NASDAQ:CNTX) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of ...

Context Therapeutics Presents New Preclini...
04/30/2025 11:37:06

Context Therapeutics Inc. ("Context" or "Company") (NASDAQ:CNTX), a clinical-stage biopharmaceutical company ad...

D. Boral Capital Maintains Buy on Context ...
04/29/2025 11:30:42

D. Boral Capital analyst Jason Kolbert maintains Context Therapeutics (NASDAQ:CNTX) with a Buy and maintains $9 price target.